Outcome of hepatitis B and C virus-associated hepatocellular carcinoma occurring after renal transplantation.

Kanaan, Nada;Raggi, Claudia;Goffin, Eric;De Meyer, Martine;Hassoun, Ziad;et.al.
(2017) Journal of Viral Hepatitis — Vol. 24, n° 5, p. 430-435 (2017)

Files

Kanaan-2017-OutcomeofhepatitisBand.pdf
  • Open Access
  • Adobe PDF
  • 334.81 KB

Details

Authors
  • Kanaan, NadaUCLouvain
    Author
  • Raggi, ClaudiaUCLouvain
    Author
  • Goffin, EricUCLouvain
    Author
  • De Meyer, MartineUCLouvain
    Author
  • Mourad, MichelUCLouvain
    Author
  • Author
  • Beguin, ClaireUCLouvain
    Author
  • Borbath, IvanUCLouvain
    Author
  • Pirson, YvesUCLouvain
    Author
  • Hassoun, ZiadUCLouvain
    Author
Show more
Abstract
Kidney transplant recipients (KTR) are subjected to immunosuppressive therapy that can enhance hepatitis B and C virus replication, leading to cirrhosis and hepatocellular carcinoma (HCC). The aim of this study was to assess the prevalence and outcome of HCC in KTR. Case-control study. Patients with chronic HBV and/or HCV infection who underwent kidney transplantation between 1976 and 2011 and subsequently developed HCC were compared to a control group of patients with chronic HBV and/or HCV infection, matched for gender and age at HCC diagnosis, who did not receive kidney transplantation. Among 2944 KTR, 330 had hepatitis B and/or C. Fourteen developed HCC, a period prevalence of 4.2%. Age at HCC diagnosis was 52.6 ± 6.5 years (53.5 ± 5.7 in controls, P=.76). Time between transplantation and HCC diagnosis was 16.7 ± 2.7 years. Six HCCs were related to HBV, six to HCV and two to co-infection with HBV and HCV. Immunosuppressive therapy was comparable in HBV, HCV and HBV+HCV patients. At diagnosis, 71% of patients met Milan criteria (65% in the control group, P=.4). Alpha-fetoprotein levels, tumour characteristics and treatment modalities were comparable between both groups. Patient survival 2 years after HCC diagnosis was 28% in KTR, compared to 68% in controls (P=.024). Survival after HCC diagnosis is significantly worse in KTR compared to nontransplanted patients with HBV and/or HCV. Prevention is crucial and should be based on viral eradication/suppression before or after transplantation.
Affiliations

Citations

Kanaan, N., Raggi, C., Goffin, E., De Meyer, M., Mourad, M., Jadoul, M., Beguin, C., Kabamba-Mukadi, B., Borbath, I., Pirson, Y., & Hassoun, Z. (2017). Outcome of hepatitis B and C virus-associated hepatocellular carcinoma occurring after renal transplantation. Journal of Viral Hepatitis, 24(5), 430-435. https://doi.org/10.1111/jvh.12655 (Original work published 2017)